비알콜성 지방간염(NASH) – 파이프라인 인사이트 2021년

■ 영문 제목 : Non-Alcoholic Steatohepatitis (NASH) - Pipeline Insights, 2021

DelveInsight 회사가 출판한 조사자료로, 코드는 DLV210SP941 입니다.■ 상품코드 : DLV210SP941
■ 조사/발행회사 : DelveInsight
■ 발행일 : 2021년1월
■ 페이지수 : 약60
■ 작성언어 : 영어
■ 보고서 형태 : PDF
■ 납품 방식 : E메일(3일)
■ 조사대상 지역 : 글로벌
■ 산업 분야 : 제약
■ 판매가격 / 옵션 (부가세별도)
Single UserUSD2,000 ⇒환산₩2,200,000견적의뢰/주문/질문
2-3 UserUSD3,000 ⇒환산₩3,300,000견적의뢰/주문/질문
Site LicenseUSD4,000 ⇒환산₩4,400,000견적의뢰/구입/질문
가격옵션 설명
- 지불하실 금액은 상기 원화금액에 부가세(10%)를 더한 금액입니다.
- 납기는 즉일~2일소요됩니다. 3일이상 소요되는 경우는 별도표기 또는 연락드립니다.
- 지불방법은 계좌이체/무통장입금 또는 카드결제이며, 세금계산서 발행 가능합니다.
■ 보고서 개요

Non-Alcoholic Steatohepatitis (NASH) of pipeline development activities
The report provides insights into:
• All of the companies that are developing therapies for the treatment of Non-Alcoholic Steatohepatitis (NASH) with aggregate therapies developed by each company for the same.
• Different therapeutic candidates segmented into early-stage, mid-stage and late stage of development for the Non-Alcoholic Steatohepatitis (NASH) treatment.
• Non-Alcoholic Steatohepatitis (NASH) key players involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of Non-Alcoholic Steatohepatitis (NASH) market.
The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university web sites and industry-specific third-party sources, etc.

Non-Alcoholic Steatohepatitis (NASH) Analytical Perspective by DelveInsight
• In-depth Non-Alcoholic Steatohepatitis (NASH) Commercial Assessment of products
This report provides a comprehensive commercial assessment of therapeutic drugs that have been included, which comprises of collaborations, licensing, and acquisition deal value trends. The report also covers company-company collaborations (licensing/partnering), company-academia collaborations, and acquisition analysis in both graphical and tabulated form in a detailed manner.
• Non-Alcoholic Steatohepatitis (NASH) Clinical Assessment of products
The report comprises of comparative clinical assessment of products by development stage, product type, route of administration, molecule type, and MOA type across this indication.

Scope of the report
• The Non-Alcoholic Steatohepatitis (NASH) report provides an overview of therapeutic pipeline activity and therapeutic assessment of the products by development stage, product type, route of administration, molecule type, and MOA type for Non-Alcoholic Steatohepatitis (NASH) across the complete product development cycle, including all clinical and nonclinical stages.
• It comprises of detailed profiles of Non-Alcoholic Steatohepatitis (NASH) therapeutic products with key coverage of developmental activities, including technology, collaborations, licensing, mergers and acquisition, funding, designations and other product-related details
• Detailed Non-Alcoholic Steatohepatitis (NASH) research and development progress and trial details, results wherever available, are also included in the pipeline study.
• Coverage of dormant and discontinued pipeline projects along with the reasons if available across Non-Alcoholic Steatohepatitis (NASH).

Report highlights
• A better understanding of disease pathogenesis contributing to the development of novel therapeutics for Non-Alcoholic Steatohepatitis (NASH).
• In the coming years, the Non-Alcoholic Steatohepatitis (NASH) market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies and academics that are working to assess challenges and seek opportunities that could influence Non-Alcoholic Steatohepatitis (NASH) R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
• A detailed portfolio of major pharma players who are involved in fueling the Non-Alcoholic Steatohepatitis (NASH) treatment market. Several potential therapies for Non-Alcoholic Steatohepatitis (NASH) are under investigation. With the expected launch of these emerging therapies, it is expected that there will be a significant impact on the Non-Alcoholic Steatohepatitis (NASH) market size in the coming years.
• Our in-depth analysis of the pipeline assets (in early-stage, mid-stage and late stage of development for the treatment of Non-Alcoholic Steatohepatitis (NASH)) includes therapeutic assessment and comparative analysis. This will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.

Key Questions
• What are the current options for Non-Alcoholic Steatohepatitis (NASH) treatment?
• How many companies are developing therapies for the treatment of Non-Alcoholic Steatohepatitis (NASH)?
• What are the principal therapies developed by these companies in the industry?
• How many therapies are developed by each company for the treatment of Non-Alcoholic Steatohepatitis (NASH)?
• How many Non-Alcoholic Steatohepatitis (NASH) emerging therapies are in early-stage, mid-stage, and late stage of development for the treatment of Non-Alcoholic Steatohepatitis (NASH)?
• Out of total pipeline products, how many therapies are given as a monotherapy and in combination with other therapies?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, and major licensing activities that will impact Non-Alcoholic Steatohepatitis (NASH) market?
• Which are the dormant and discontinued products and the reasons for the same?
• What is the unmet need for current therapies for the treatment of Non-Alcoholic Steatohepatitis (NASH)?
• What are the recent novel therapies, targets, mechanisms of action and technologies developed to overcome the limitation of existing Non-Alcoholic Steatohepatitis (NASH) therapies?
• What are the clinical studies going on for Non-Alcoholic Steatohepatitis (NASH) and their status?
• What are the results of the clinical studies and their safety and efficacy?
• What are the key designations that have been granted for the emerging therapies for Non-Alcoholic Steatohepatitis (NASH)?
• How many patents are granted and pending for the emerging therapies for the treatment of Non-Alcoholic Steatohepatitis (NASH)?

■ 보고서 목차

1. Report Introduction

2. Non-Alcoholic Steatohepatitis (NASH)

2.1. Overview

2.2. History

2.3. Non-Alcoholic Steatohepatitis (NASH) Symptoms

2.4. Causes

2.5.Pathophysiology

2.6. Non-Alcoholic Steatohepatitis (NASH) Diagnosis

2.6.1. Diagnostic Guidelines

3. Non-Alcoholic Steatohepatitis (NASH) Current Treatment Patterns

3.1. Non-Alcoholic Steatohepatitis (NASH) Treatment Guidelines

4. Non-Alcoholic Steatohepatitis (NASH) – DelveInsight’s Analytical Perspective

4.1. In-depth Commercial Assessment

4.1.1. Non-Alcoholic Steatohepatitis (NASH) companies collaborations, Licensing, Acquisition -Deal Value Trends

4.1.1.1. Assessment Summary

4.1.2. Non-Alcoholic Steatohepatitis (NASH) Collaboration Deals

4.1.2.1. Company-Company Collaborations (Licensing / Partnering) Analysis

4.1.2.2. Company-University Collaborations (Licensing / Partnering) Analysis

4.1.2.3. Non-Alcoholic Steatohepatitis (NASH) Acquisition Analysis

5. Therapeutic Assessment

5.1. Clinical Assessment of Pipeline Drugs

5.1.1. Assessment by Phase of Development

5.1.2. Assessment by Product Type (Mono / Combination)

5.1.2.1. Assessment by Stage and Product Type

5.1.3. Assessment by Route of Administration

5.1.3.1. Assessment by Stage and Route of Administration

5.1.4. Assessment by Molecule Type

5.1.4.1. Assessment by Stage and Molecule Type

5.1.5. Assessment by MOA

5.1.5.1. Assessment by Stage and MOA

5.1.6. Assessment by Target

5.1.6.1. Assessment by Stage and Target

6. Non-Alcoholic Steatohepatitis (NASH) Late Stage Products (Phase-III)

7. Non-Alcoholic Steatohepatitis (NASH) Mid Stage Products (Phase-II)

8. Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Non-Alcoholic Steatohepatitis (NASH) Discontinued Products

13. Non-Alcoholic Steatohepatitis (NASH) Product Profiles

13.1. Drug Name: Company

13.1.1. Product Description

13.1.1.1. Product Overview

13.1.1.2. Mechanism of action

13.1.2. Research and Development

13.1.2.1. Clinical Studies

13.1.3. Product Development Activities

13.1.3.1. Collaboration

13.1.3.2. Agreements

13.1.3.3. Acquisition

13.1.3.4. Patent Detail

13.1.4. Tabulated Product Summary

13.1.4.1. General Description Table

Detailed information in the report?

14. Non-Alcoholic Steatohepatitis (NASH) Key Companies

15. Non-Alcoholic Steatohepatitis (NASH) Key Products

16. Dormant and Discontinued Products

16.1. Dormant Products

16.1.1. Reasons for being dormant

16.2. Discontinued Products

16.2.1. Reasons for the discontinuation

17. Non-Alcoholic Steatohepatitis (NASH) Unmet Needs

18. Non-Alcoholic Steatohepatitis (NASH) Future Perspectives

19. Non-Alcoholic Steatohepatitis (NASH) Analyst Review

20. Appendix

21. Report Methodology

21.1. Secondary Research

21.2. Expert Panel Validation

※본 조사보고서 [비알콜성 지방간염(NASH) – 파이프라인 인사이트 2021년] (코드 : DLV210SP941) 판매에 관한 면책사항을 반드시 확인하세요.
※본 조사보고서 [비알콜성 지방간염(NASH) – 파이프라인 인사이트 2021년] 에 대해서 E메일 문의는 여기를 클릭하세요.